ZBIO Investor Reminder: Cohen Milstein Encourages Zenas BioPharma Investors to Consider Leading Class Action Following IPO Stock Collapse

/EIN News/ -- WASHINGTON, April 29, 2025 (GLOBE NEWSWIRE) -- Cohen Milstein Sellers & Toll PLLC, a nationally prominent securities litigation firm, announces that retail and institutional investors who purchased shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the company's September 2024 initial public offering remain eligible to seek appointment as lead plaintiff in a securities class action lawsuit. The deadline to move for lead plaintiff is June 16, 2025.

[Click here for information about joining the class action]

If you’d like to discuss this matter or your rights before signing up, please contact Molly J. Bowen, a partner at Cohen Milstein, at (202) 408-4600 or mbowen@cohenmilstein.com.

About the Case:
The lawsuit, filed in the U.S. District Court for the District of Massachusetts, alleges that Zenas BioPharma’s IPO registration materials misrepresented the company’s financial condition—specifically overstating the period it could fund operations. Initially claiming it could fund operations for 24 months, Zenas BioPharma later revealed, in its November 2024 SEC filing, that available capital would only support 12 months. Following this disclosure, the company's stock plummeted nearly 49%, closing at $8.72 on April 15, 2025.

Why Serve as Lead Plaintiff?
The lead plaintiff has the critical role of representing the class and helping guide the strategy and settlement of the litigation. While any shareholder who purchased during the IPO period can share in a recovery, those who are appointed lead plaintiff will get to play a meaningful and significant role in overseeing the case.

Why Cohen Milstein?
Cohen Milstein has earned a reputation as one of the most formidable forces in securities fraud litigation. With more than 100 attorneys across eight offices nationwide, the firm is perennially recognized by Chambers USA, The National Law Journal, Law360, and The Legal 500 as a leader in complex litigation.

Cohen Milstein has secured billions for investors, including serving as co-lead counsel in the landmark In re Wells Fargo Securities Litigation (S.D.N.Y.), which resulted in over $1 billion in recovery—one of the largest securities class action settlements in recent years.

Take the Lead:
If you sustained losses in Zenas BioPharma’s IPO and want to play an active role in recovering damages for yourself and other investors, please contact Cohen Milstein today.

CONTACT:
Molly Bowen, Esq.
Licensed in DC, Florida, and Ohio
Cohen Milstein Sellers & Toll PLLC
1100 New York Avenue, N.W., Fifth Floor
Washington, D.C. 20005
Phone: (888) 240-0775 or (202) 408-4600
Email: mbowen@cohenmilstein.com
Website: www.cohenmilstein.com

Attorney Advertising. Prior results do not guarantee a similar outcomes.